ProPhase Labs, Inc. Operating Lease, Payments
ProPhase Labs, Inc. (PRPH) reported Operating Lease, Payments of $1.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q/A filed 2026-07-09.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-19
- ProPhase Labs, Inc. operating lease, payments for the quarter ending 2026-03-31 was $1.00K, a 0.00% change year-over-year.
- ProPhase Labs, Inc. operating lease, payments for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. operating lease, payments for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. operating lease, payments for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. operating lease, payments for fiscal 2025 was $1.00K, a 99.86% decline from fiscal 2024.
- ProPhase Labs, Inc. operating lease, payments for fiscal 2024 was $716.00K, a 14.66% decline from fiscal 2023.
- ProPhase Labs, Inc. operating lease, payments for fiscal 2023 was $839.00K, a 8.40% increase from fiscal 2022.
- ProPhase Labs, Inc. operating lease, payments for fiscal 2022 was $774.00K, a 116.81% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.00K 10-Q/A · filed 2026-07-09 | $1.00K derived: sum of 2 quarters · filed 2026-07-09 | $1.00K derived: sum of 3 quarters · filed 2026-07-09 | $1.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $0.00 derived: sum of 2 quarters · filed 2026-06-01 | $0.00 derived: sum of 3 quarters · filed 2026-08-19 | $1.00K 10-K · filed 2026-06-01 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $0.00 derived: sum of 2 quarters · filed 2026-08-19 | $1.00K 10-Q · filed 2025-11-19 | $3.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | $1.00K 10-Q · filed 2026-08-19 | $3.00K derived: sum of 3 quarters · filed 2026-08-19 | $241.00K derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | $1.00K 10-Q/A · filed 2026-07-09 | $3.00K derived: sum of 2 quarters · filed 2026-07-09 | $241.00K derived: sum of 3 quarters · filed 2026-07-09 | $479.00K derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | $240.00K derived: sum of 2 quarters · filed 2026-06-01 | $478.00K derived: sum of 3 quarters · filed 2026-06-01 | $716.00K 10-K · filed 2026-06-01 |
| 2024-09-30 | $238.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | $476.00K derived: sum of 2 quarters · filed 2025-11-19 | $714.00K 10-Q · filed 2025-11-19 | $947.00K derived: sum of 4 quarters · filed 2025-11-19 |
| 2024-06-30 | $238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $476.00K 10-Q · filed 2025-08-13 | $709.00K derived: sum of 3 quarters · filed 2025-08-13 | $918.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $238.00K 10-Q · filed 2025-05-20 | $471.00K derived: sum of 2 quarters · filed 2025-05-20 | $680.00K derived: sum of 3 quarters · filed 2025-05-20 | $879.00K derived: sum of 4 quarters · filed 2025-05-20 |
| 2023-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-01 | $442.00K derived: sum of 2 quarters · filed 2025-04-01 | $641.00K derived: sum of 3 quarters · filed 2025-04-01 | $839.00K 10-K · filed 2025-04-01 |
| 2023-09-30 | $209.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $408.00K derived: sum of 2 quarters · filed 2024-11-13 | $606.00K 10-Q · filed 2024-11-13 | $800.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $397.00K 10-Q · filed 2024-08-14 | $591.00K derived: sum of 3 quarters · filed 2024-08-14 | $784.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $198.00K 10-Q · filed 2024-05-10 | $392.00K derived: sum of 2 quarters · filed 2024-05-10 | $585.00K derived: sum of 3 quarters · filed 2024-05-10 | |
| 2022-12-31 | $194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $387.00K derived: sum of 2 quarters · filed 2024-03-29 | $774.00K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $193.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $580.00K 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $387.00K 10-Q · filed 2023-08-11 | |||
| 2021-12-31 | $189.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $321.00K derived: sum of 2 quarters · filed 2023-03-29 | $339.00K derived: sum of 3 quarters · filed 2023-03-29 | $357.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $132.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $150.00K derived: sum of 2 quarters · filed 2022-11-10 | $168.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $36.00K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $18.00K 10-Q · filed 2021-05-14 | |||
| 2020-12-31 | $11.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |